Publications

Featured Publications

• Human muscle stem cells are refractory to aging

  Novak JS, Mázala DAG, Nearing M, Hindupur R, Uapinyoying P, Habib NF, Dickson T, Ioffe OB, Harris BT, Fidelia-Lambert MN, Rossi CT, Hill DA, Wagner KR, Hoffman EP, Partridge TA PMID: 34089289 Aging Cell doi.org/10.1111/acel.13411 (2021)

• TGF-beta-driven muscle degeneration and failed regeneration underlie disease onset in DMD mouse model

  Mázala DA*, Novak JS*, Hogarth MW, Nearing M, Adusumalli P, Tully CB, Habib NF, Gordish-Dressman H, Chen YW, Jaiswal JK, Partridge TA *Denotes joint first-authorship PMID: 32213706 JCI Insight 5(6). PMID: 32213706 (2020)

• Membrane repair deficit in facioscapulohumeral muscular dystrophy

  Bittel AJ, Sreetama SC, Bittel DC, Horn A, Novak JS, Yokota T, Zhang A, Maruyama R, Lim KRQ, Jaiswal JK, Chen YW PMID: 32759720 International Journal of Molecular Sciences 21(15):E5575 (2020)

• Mitochondrial dysfunction and role of hara-kiri in the pathogenesis of myositis

  Boehler JF, Horn A, Novak JS, Li N, Ghimbovschi S, Lundberg IE, Alexanderson H, Munters LA, Jaiswal JK, Nagaraju K PMID: 31135059 Journal of Pathology 249(2):215-226 (2019)

• Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice

  Vila MC*, Novak JS*, Hogarth MW, Klimek MB, Boehler J, Gordish-Dressman H, van den Anker J, Yokota T, Lu QL, Hoffman EP, Partridge TA, Nagaraju K. *Denotes joint first-authorship PMID: 30883742 Journal of Pathology 248(3): 339-351 (2019)

• Greater colo-rectal activation phenotype in exercised mdx mice

  Nearing M, Novak JS, Partridge TA PMID: 39862132 PLoS Currents 10 (2018)

• Shorter phosphorodiamidate morpholino antisense oligonucleotides (PMO-AONs) in higher doses may increase exon skipping efficacy in Duchenne muscular dystrophy patients

  Akpulat U, Becker K, Partridge TA, Novak JS, Cirak S PMID: 30396145 Molecular Therapy 13: 534-542 (2018)

• The macrophage as a Trojan horse for antisense oligonucleotide delivery

  Novak JS, Jaiswal JK, Partridge TA PMID: 29860876 Expert Opinion Therapeutic Targets 22:463-466 (2018)

• Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle

  Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA PMID: 29038471 Nature Communications 8:941 (2017)

• Effect of endurance exercise on microRNAs in myositis skeletal muscle – a randomized controlled study

  Boehler JF, Hogarth MW, Barberio MD, Novak JS, Ghimbovschi S, Brown KJ, Munters LA, Loell I, Chen Y-W, Gordish-Dressman H, Alexanderson H, Lundberg IE, Nagaraju K PMID: 28829792 PLoS One 12(18): e0183292 (2017)

• Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy

  Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T PMID: 28865998 Molecular Therapy 25:2561-2572 (2017)

• Effect of genetic background on the dystrophic phenotype in mdx mice

  Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen JH, Rayavarapu S, Novak JS, Nearing M, Quinn JL, Saunders A, Dolan C, Andrews W, Lammert C, Austin A, Partridge TA, Cox GA, Lutz C, Nagaraju K PMID: 26566673 Human Molecular Genetics 25:130-145 (2016)

• Elusive sources of variability of dystrophin rescue by exon skipping

  Vila MC, Klimek MB, Novak JS, Rayavarapu S, Uaesoontrachoon K, Boehler JF, Fiorillo AA, Hogarth MW, Zhang A, Shaughnessy C, Gordish-Dressman H, Burki U, Straub V, Lu QL, Partridge TA, Brown KJ, Hathout Y, van den Anker J, Hoffman EP, Nagaraju K PMID: 26634117 Skeletal Muscle 5:44 (2015)

• TNF-alpha-induced microRNAs control dystrophin expression in Becker muscular dystrophy

  Fiorillo AA, Heier CR, Novak JS, Tully CB, Brown KJ, Uaesoontrachoon K, Vila MC, Ngheim PP, Bello L, Kornegay JN, Angelini C, Partridge TA, Nagaraju K, Hoffman EP PMID: 26321630 Cell Reports 12:1678-1690 (2015)

• Germline quality control: eEF2K stands guard to eliminate defective oocytes

  Chu HP*, Liao Y*, Novak JS*, Hu Z, Merkin JJ, Shymkiv Y, Braeckman BP, Dorovkov MV, Nguyen A, Clifford PM, Nagele RG, Harrison DE, Ellis RE, Ryazanov AG *Denotes joint first-authorship PMID: 24582807 Developmental Cell 28:561-572 (2014)